ERIS

Eris Lifesciences Share Price

₹1,370.55 +2.1 (0.15%)

21 Nov, 2024 14:31

SIP TrendupStart SIP in ERIS

Start SIP

Performance

  • Low
  • ₹1,349
  • High
  • ₹1,377
  • 52 Week Low
  • ₹809
  • 52 Week High
  • ₹1,522
  • Open Price₹1,375
  • Previous Close₹1,368
  • Volume22,337

Investment Returns

  • Over 1 Month + 1.72%
  • Over 3 Month + 13.13%
  • Over 6 Month + 52.52%
  • Over 1 Year + 49.24%
SIP Lightning

Smart Investing Starts Here Start SIP with Eris Lifesciences for Steady Growth!

Invest Now

Eris Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 53.5
  • PEG Ratio
  • -5.6
  • Market Cap Cr
  • 18,654
  • P/B Ratio
  • 7.2
  • Average True Range
  • 52.07
  • EPS
  • 25.6
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.11
  • RSI
  • 57.8
  • MFI
  • 71.92

Eris Lifesciences Financials

Eris Lifesciences Technicals

EMA & SMA

Current Price
₹1,370.55
+ 2.1 (0.15%)
pointer
  • stock-down_img
  • Bullish Moving Average 16
  • stock-up_img
  • Bearish Moving Average 0
  • 20 Day
  • ₹1,332.39
  • 50 Day
  • ₹1,315.87
  • 100 Day
  • ₹1,247.82
  • 200 Day
  • ₹1,130.23

Resistance and Support

1381.68 Pivot Speed
  • R3 1,516.82
  • R2 1,476.18
  • R1 1,422.32
  • S1 1,327.82
  • S2 1,287.18
  • S3 1,233.32

What's your outlook on Eris Lifesciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Eris Lifesciences Ltd. is a leading Indian pharmaceutical company specializing in chronic and sub-chronic therapies. With 70% in-house manufacturing and a pan-India distribution network, Eris generates 86% of its revenue from chronic care, serving over 500,000 chemists nationwide.

Eris Lifesciences has an operating revenue of Rs. 2,495.89 Cr. on a trailing 12-month basis. An annual revenue growth of 20% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company has a reasonable debt to equity of 25%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 27% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It is currently FORMING a base in its weekly chart and is trading around 5% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 40 which is a POOR score indicating inconsistency in earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 85 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Eris Lifesciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-25 Quarterly Results
2024-08-02 Quarterly Results
2024-05-21 Audited Results & Fund Raising
2024-02-13 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2022-08-16 INTERIM Rs.7.35 per share(735%)Interim Dividend
2021-08-06 INTERIM Rs.6.01 per share(601%)Interim Dividend

Eris Lifesciences F&O

Eris Lifesciences Shareholding Pattern

54.87%
17.03%
0.92%
8.01%
0%
10.52%
8.65%

About Eris Lifesciences

  • NSE Symbol
  • ERIS
  • BSE Symbol
  • 540596
  • Chairperson & Managing Director
  • Mr. Amit Bakshi
  • ISIN
  • INE406M01024

Similar Stocks to Eris Lifesciences

Eris Lifesciences FAQs

Eris Lifesciences share price is ₹1,370 As on 21 November, 2024 | 14:17

The Market Cap of Eris Lifesciences is ₹18654 Cr As on 21 November, 2024 | 14:17

The P/E ratio of Eris Lifesciences is 53.5 As on 21 November, 2024 | 14:17

The PB ratio of Eris Lifesciences is 7.2 As on 21 November, 2024 | 14:17

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23